

# President Annual Activity Report for 2018

**Nicolaus Kröger, EBMT President**



# EBMT

European Society  
for Blood and Marrow  
Transplantation

## Achievements in 2018 at a glance

### SCIENCE

- **> 250** ongoing projects
- **118** publications in peer-reviewed journals
- **98** oral presentations at international meetings
- **40,653** transplants reported to the **Registry**
- **EMA** draft positive qualification opinion of the cellular therapy module of the Registry > qualification opinion 28 Feb. 2019
- **45,418** HSCT reported to the **Activity Survey** in 2018

### EDUCATION

- **EBMT 44<sup>th</sup> Annual Meeting:**  
5,261 delegates from 87 countries
- **20** educational events including the 3<sup>rd</sup> ITC
- New **EBMT Handbook**

### PATIENT CARE

#### JACIE


- **75** received applications
- **78** performed inspections
- **51** awarded accreditations
- 7<sup>th</sup> Edition of the FACT-JACIE standards

• 9 NHS centres achieved JACIE accreditation for IEC administration

#### NURSES GROUP


- Educational meetings incl. paediatric training days and the 2nd training course for HSCT Nurses in India
- Textbook for Nurses
- Collaborative research projects

# SCIENCE



# The EBMT Registry

Total of > 567,500 PATIENTS and 670,000 TRANSPLANTS



- **40,653** transplants were registered during 2018

- *Transplants that took place in 2018 are still being registered*

# The EBMT Registry



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

## EMA'S QUALIFICATION OPINION ON CELLULAR THERAPY MODULE OF EBMT REGISTRY

29<sup>th</sup> June 2018: EMA released their draft qualification opinion on the cellular therapy module of the EBMT registry for public consultation.

28<sup>th</sup> February 2019: EBMT Registry qualified as a **suitable platform for the collection of data for post-authorisation safety study (PASS)**.

## CELL THERAPY

The EBMT has further worked on the Cell Therapy Med-A form, resulting in the creation of a new **Cellular and Gene Therapy**.

The EBMT has been working with commercial CAR-T manufacturers to review and validate the Cellular and Gene Therapy Form to incorporate the remaining “must have” items required by EMA.



## REGISTRY UPGRADE

**The new Registry system (MACRO) is coming closer to go-live date.**

During 2018, comprehensive testing of Data Entry continued, alongside the initial testing of the new Data Retrieval function, following further customised development for EBMT.

Thanks to the pool of beta testers - EBMT staff, National Registry staff and Centre data managers - who volunteered their time and gave important feedback.

# Transplant Activity Survey

In 2017, 683 teams reported 45,418 transplants in 41,100 patients (first transplant) to the annual activity survey.

Bone Marrow Transplantation  
<https://doi.org/10.1038/s41409-019-0465-9>



## ARTICLE



### The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies

Jakob R. Passweg<sup>1</sup> · Helen Baldomero<sup>1</sup> · Grzegorz W. Basak<sup>2</sup> · Christian Chabannon<sup>3</sup> · Selim Corbacioglu<sup>4</sup> · Rafael Duarte<sup>5</sup> · Jürgen Kuball<sup>6</sup> · Arjan Lankester<sup>7</sup> · Silvia Montoto<sup>8</sup> · Régis Peffault de Latour<sup>9</sup> · John A. Snowden<sup>10</sup> · Jan Styczynski<sup>11</sup> · Ibrahim Yakoub-Agha<sup>12</sup> · Mutlu Arat<sup>13</sup> · Mohamad Mohty<sup>14</sup> · Nicolaus Kröger<sup>15</sup> · for the European Society for Blood and Marrow Transplantation (EBMT)



Received: 21 December 2018 / Accepted: 26 December 2018  
© The Author(s) 2019. This article is published with open access

#### Abstract

Hematopoietic cell transplantation (HCT) is widely used for acquired and congenital disorders of the hematopoietic system. Number of transplants done in Europe and associated countries continues to rise with 45,418 HCT in 41,100 patients [(17,155 allogeneic (42%) and 23,945 autologous (58%)] reported by 683 centers in 50 countries in 2017. Main indications were myeloid malignancies 10,147 (25%; 96% allogeneic), lymphoid malignancies 26,488 (64%; 19% allogeneic), solid tumors 1,607 (3.9%; 2% allogeneic), and nonmalignant disorders 2,667 (7%; 81% allogeneic). Trends in donor choice seen before continue, with growing numbers of haploidentical HCT and decreasing use of cord blood. Of interest is that after many years of continued growth, the number of patients receiving an allogeneic HCT for marrow failure is decreasing slightly ( $p < 0.001$ ). Such a change may be explained by the use of thrombopoietin analogs in aplastic anemia patients. Other nonmalignant indications, however continue to grow, most importantly HCT for hemoglobinopathies by 36%, equally for thalassemias and sickle cell disease. Non-HCT cell therapies have increased by 28% since 2015 and genetically modified T cells is type of cell therapy with the fastest growth. These annual reports reflect current activity and trends and are useful for health-care planning.

# High scientific productivity

118 EBMT publications in highly-ranked peer-reviewed journals.



# EDUCATION





# EBMT 2018

## 44th Annual Meeting

18-21 March 2018 in Lisbon, Portugal

### Attendance



**5,261**

delegates from



**87**

countries

#### Top ten countries



### Programme



**1,213**

abstracts submitted



**192**

oral presentations



**971**

posters presented



**171**

sessions



**15**

awards

# High educational productivity


## EDUCATIONAL EVENTS

20 cutting-edge educational events and courses organised by the 10 Working Parties; Nurses Group and JACIE and attended by more than 1,500 participants in total.




## EBMT HANDBOOK

Release of the new EBMT Handbook in January 2019. The project started in 2017. The Handbook is composed of 93 chapters written by 175 leading experts in the field.




## E-LEARNING PLATFORM

The process for developing an e-learning platform to further educate the EBMT community has started in 2018.




# PATIENT CARE



# Standards & Accreditation


## 75 APPLICATIONS

(30 first-time and 45 reaccreditation) received




## 78 INSPECTIONS

(19 first-time and 59 reaccreditation) received



## 51 ACCREDITATIONS

(9 first-time and 42 reaccreditation) awarded



3 JACIE training courses with 60 participants in total.

# Two significant events



The **1<sup>st</sup> joint JACIE-FACT inspection in Latin America** was performed in November 2018 in Córdoba, Argentina.

A further 10 centres from the region have presented themselves to be accredited during 2019-2020. This is the first region in which the **StepWise** approach to accreditation is being tested.



Nine centres in England achieved accreditation for **immune effector cell administration** (IEC) in conjunction with NHS England as part of their CAR-T cell therapy roll-out strategy.

Both of these special initiatives impacted on the JACIE's applications, inspections and accreditations activities in 2018.

# 7th Edition of the FACT-JACIE Standards



Published on 1 March 2018. This edition featured Immune Effector Cells (IEC), first developed in edition 6.1.

These particular standards have sparked a lot of interest given the recent upsurge in CAR-T cellular therapy activity.

# EBMT Nurses Group

## EDUCATION


The 6<sup>th</sup> Paediatricians & Paediatric Nurses training course on HSCT in Children and Adolescents (7-9 June in Verona, Italy) was a great success with nurses across Europe attending.

10<sup>th</sup> Training Day and 2<sup>nd</sup> Research Day

The Global Educational Committee visited the ACTREC hospital in Mumbai, India (14-15 Dec. 2018) to give a series of presentations focused on JACIE Nursing specific standards. Approx. 220 nurses attended this educational program.

## THE TEXTBOOK FOR NURSES

Released: March 2018



## RESEARCH

Two publications in *Bone Marrow Transplantation*.

Several projects currently recruiting or about to be launched by the EBMT nurses research group.

# Creation of the EBMT Patient, Family and Donor Committee

The Committee is composed of patient advocates of EU patient organisations representing patients with haematological diseases, and national patient associations as well as a representative of the EBMT Nurses Group from the country where the upcoming Annual Meeting is taking place to participate in the organisation of Patient, Family and Donor Day.

More here: <https://www.ebmt.org/patient-family-and-donor-committee>



# Other achievements

# Launch of the EBMT New Website

Went live on the 12<sup>th</sup> of March 2018 and was presented at the EBMT booth during the Annual Meeting in Lisbon.



**57% increase in new visits**

Visitor traffic rising

**58% improvement on return visits**

Loyalty ascending

**80.70% page views boost**

Page views boost

**Mobile visits rocketed from 1% to 16%**

Mobile visits

**65%** of the Annual Meeting  
organisational activities are  
managed by the EBMT.



# Thank you